Healthcare Industry News:  H. Lundbeck 

Biopharmaceuticals Litigation

 News Release - July 11, 2006

Forest Laboratories, Inc. and H. Lundbeck A/S File Lawsuit Against Caraco Pharmaceutical Laboratories, Ltd. for Patent Infringement

NEW YORK, July 11 (HSMN NewsFeed) -- Forest Laboratories, Inc. (NYSE: FRX ), Forest Laboratories Holdings, Ltd. and H. Lundbeck A/S announced that they have filed a lawsuit in the U.S. District Court for the Eastern District of Michigan against Caraco Pharmaceutical Laboratories, Ltd. for infringement of U.S. Patent Re. No. 34,712, which relates to Forest's Lexapro® product.

Forest has received notification from Caraco Pharmaceutical Laboratories, Ltd. that it filed an Abbreviated New Drug Application (ANDA) with a Paragraph IV Certification for a generic equivalent to Lexapro®.

Howard Solomon, Chairman and Chief Executive Officer of Forest, said: "We believe the patent on Lexapro is valid and enforceable. Just as we did in our prior patent litigations against Ivax Pharmaceuticals and Alphapharm, we intend to prosecute this lawsuit vigorously."

Except for the historical information contained herein, this release contains "forward-looking statements" within the meaning of the Private Securities Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in the Forest Laboratories' SEC reports, including the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2006.

Source: Forest Laboratories

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.